<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02872025</url>
  </required_header>
  <id_info>
    <org_study_id>16704</org_study_id>
    <nct_id>NCT02872025</nct_id>
  </id_info>
  <brief_title>Pembrolizumab in High-risk Ductal Carcinoma in Situ (DCIS)</brief_title>
  <official_title>Testing the Ability of Pembrolizumab to Alter the Tumor Immune MicroEnvironment (TIME) of High Risk DCIS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laura Esserman</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study to investigate the change in the immune microenvironment of high risk
      ductal carcinoma in situ (DCIS) after short term exposure to pembrolizumab.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will include 3 dose cohorts using a 3+3 cohort dose escalation design (see figure
      1) followed by a 4th cohort at the maximum tolerated dose. Unless a dose limiting toxicity
      (DLT), defined any grade 3 or 4 toxicity, is observed requiring expansion of a cohort or a
      subject withdraws, 3 subjects will be enrolled into each cohort in the dose escalation phase.
      Subjects, upon diagnosis with high risk DCIS, will be offered 2 doses of pembrolizumab
      injected intralesionally (IL) 3 weeks apart (+/- 1 week) with surgery 3 weeks (+/- 2 weeks)
      after the 2nd dose. The subject will then undergo the surgical treatment as determined by the
      surgeon and the subject (partial mastectomy or mastectomy). The primary objective of this
      phase of the study will be safety and feasibility of intralesional injection of
      pembrolizumab. The maximum tolerated dose will be used in the expansion phase. The expansion
      cohort will have a target enrollment of 30 subjects randomized to either the control group or
      the treatment group. 10 subjects will be randomized to the control group and 20 subjects will
      be randomized to the treatment group. The control group will proceed to surgery alone
      following the diagnosis of high risk DCIS. The treatment group will receive 2 doses of
      intralesional pembrolizumab 3 weeks apart (+/- 1 week) prior to surgery. All subjects in the
      expansion cohort will also undergo a baseline MRI at diagnosis and undergo a 2nd MRI prior to
      surgery. Baseline and pre-surgical MRI images will be evaluated for changes in tumor volume.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 12, 2016</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD)</measure>
    <time_frame>18 months</time_frame>
    <description>To determine the maximum tolerated dose (MTD), and recommended dose for subsequent expansion cohort, of intralesionally administered pembrolizumab in patients with ductal carcinoma in situ (DCIS) of the breast.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-limiting toxicities (DLTs)</measure>
    <time_frame>18 months</time_frame>
    <description>To define the dose-limiting toxicities (DLTs), tolerability, and feasibility of intralesional administration of pembrolizumab in patients with DCIS.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of patients who demonstrate an increase (baseline vs. post intralesional injection) in intralesional CD8+ T cells (treated vs. untreated participants) as measured using multiplex immunofluorescence on FFPE tissue sections</measure>
    <time_frame>post intralesional injection</time_frame>
    <description>To determine the response rate to intralesional pembrolizumab in patients with DCIS, as measured by an increase (baseline vs. post treatment) in intralesional CD8+ T cells, compared to untreated controls.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Tumor volume</measure>
    <time_frame>18 months</time_frame>
    <description>To determine whether intralesional pembrolizumab decreases tumor volume on MRI imaging.</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory immunological responses to pembrolizumab before and after intralesional injection as measured using multiplex immunofluorescence on FFPE tissue sections</measure>
    <time_frame>18 months</time_frame>
    <description>To characterize changes in the immune landscape of DCIS following intralesional administration of pembrolizumab.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Carcinoma, Intraductal, Noninfiltrating</condition>
  <arm_group>
    <arm_group_label>Pembrolizumab intralesionally (IL) x 2 doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects, upon diagnosis with high risk DCIS, will be offered 2 doses of pembrolizumab injected intralesionally (IL) 3 weeks apart (+/- 1 week) with surgery 3 weeks (+/- 2 weeks) after the 2nd dose. The subject will then undergo the surgical treatment as determined by the surgeon and the subject (partial mastectomy or mastectomy).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No active treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The control group will proceed to surgery alone following the diagnosis of high risk DCIS.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <arm_group_label>Pembrolizumab intralesionally (IL) x 2 doses</arm_group_label>
    <other_name>Keytruda</other_name>
    <other_name>MK-3475</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Plan on having surgical treatment to remove the lesion

          -  Have at least 2 of the following high risk features associated with her DCIS -
             high-grade (grade II-III), palpable mass, hormone receptor negative (less than 1%),
             Her2 positive, young age (less than 45 years old), and large size (greater than 5 cm)

          -  Patients with a history of tamoxifen and/or aromatase inhibitor use for treatment or
             prevention are eligible but should discontinue these medications at least 2 weeks
             prior to starting this trial

          -  Be willing and able to provide written informed consent/assent for the trial.

          -  Be &gt;=18 years of age on day of signing informed consent.

          -  Have a performance status of 0 or 1 on the ECOG Performance Scale.

          -  Demonstrate adequate organ function as defined in Table 1 Adequate Organ Function
             Laboratory Values

          -  All screening labs should be performed within 10 days of treatment initiation.

          -  Hematological Absolute Neutrophil Count (ANC) &gt;=1,500/mcL Platelets &gt;=100,000/mcL
             Hemoglobin &gt;=9 g/dL or &gt;=5.6 mmol/L without transfusion or EPO dependency (within 7
             days of assessment)

          -  Renal Serum creatinine &lt;=1.5 X upper limit of normal (ULN) OR Measured or calculated
             creatinine clearance (GFR can also be used in place of creatinine or CrCl) &gt;=60 mL/min
             for subject with creatinine levels &gt; 1.5 X institutional ULN

          -  Hepatic Serum total bilirubin &lt;=1.5 xULN OR Direct bilirubin &lt;= ULN for subjects with
             total bilirubin levels &gt; 1.5 ULN AST (SGOT) and ALT (SGPT) &lt;= 2.5 X ULN Albumin
             &gt;=2.5mg/dL

          -  Coagulation International Normalized Ratio (INR) or Prothrombin Time (PT) &lt;=1.5 X ULN
             unless subject is receiving anticoagulant therapy as long as PT or PTT is within
             therapeutic range of intended use of anticoagulants Activated Partial Thromboplastin
             Time (aPTT) &lt;=1.5 X ULN unless subject is receiving anticoagulant therapy as long as
             PT or PTT is within therapeutic range of intended use of anticoagulants

          -  Female subjects of childbearing potential should have a negative urine or serum
             pregnancy within 72 hours prior to receiving the first dose of study medication. If
             the urine test is positive or cannot be confirmed as negative, a serum pregnancy test
             will be required.

          -  Female subjects of childbearing potential should be willing to use 2 methods of birth
             control or be surgically sterile, or abstain from heterosexual activity for the course
             of the study through 120 days after the last dose of study medication (Reference
             Section 5.7.2). Subjects of childbearing potential are those who have not been
             surgically sterilized or have not been free from menses for &gt; 1 year.

        Exclusion Criteria:

          -  Is currently participating and receiving study therapy or has participated in a study
             of an investigational agent and received study therapy or used an investigational
             device within 4 weeks of the first dose of treatment.

          -  Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any
             other form of immunosuppressive therapy within 7 days prior to the first dose of trial
             treatment.

          -  Is not interested in surgical treatment of her DCIS

          -  Has invasive breast cancer

          -  Has a known history of active TB (Bacillus Tuberculosis)

          -  Hypersensitivity to pembrolizumab or any of its excipients.

          -  Has a known additional malignancy that is progressing or requires active treatment.
             Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the
             skin that has undergone potentially curative therapy or in situ cervical cancer.

          -  Has active autoimmune disease that has required systemic treatment in the past 2 years
             (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive
             drugs). Replacement therapy (e.g.,, thyroxine, insulin, or physiologic corticosteroid
             replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a
             form of systemic treatment.

          -  Has history of/active pneumonitis that required/is requiring steroid treatment or had
             history of/active interstitial lung disease. Has an active infection requiring
             systemic therapy.

          -  Has a history or current evidence of any condition, therapy, or laboratory abnormality
             that might confound the results of the trial, interfere with the subject's
             participation for the full duration of the trial, or is not in the best interest of
             the subject to participate, in the opinion of the treating investigator.

          -  Has known psychiatric or substance abuse disorders that would interfere with
             cooperation with the requirements of the trial.

          -  Is pregnant or breastfeeding, or expecting to conceive or father children within the
             projected duration of the trial, starting with the pre-screening or screening visit
             through 120 days after the last dose of trial treatment.

          -  Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent.

          -  Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).

          -  Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA
             [qualitative] is detected).

          -  Has received a live vaccine within 30 days of planned start of study therapy. Note:
             Seasonal influenza vaccines for injection are generally inactivated flu vaccines and
             are allowed; however intranasal influenza vaccines (e.g., Flu-MistÂ®) are live
             attenuated vaccines, and are not allowed.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Katherine Forster</last_name>
    <phone>415-885-7691</phone>
    <email>katherine.forster@ucsf.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2016</study_first_submitted>
  <study_first_submitted_qc>August 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2016</study_first_posted>
  <last_update_submitted>October 24, 2017</last_update_submitted>
  <last_update_submitted_qc>October 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Laura Esserman</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Intraductal, Noninfiltrating</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

